Pfizer-BioNTech and Moderna Poised to Make Billions on COVID-19 Boosters

Moderna and the Pfizer-BioNTech alliance could reap billions from COVID-19 booster shots in the coming years, in what analysts and investors say could be a market comparable to the $6 billion in annual sales for flu vaccines. Pfizer, its German partner BioNTech, and Moderna have together locked in over $60 billion in sales of their respective COVID-19 vaccines through 2022, with the agreements covering initial doses and booster shots, according to Reuters. Analysts cited by the outlet predict revenues of over $6.6 billion for the Pfizer-BioNTech alliance and $7.6 billion for Moderna, chiefly from booster shots. Over a longer-term horizon, they predict the market will eventually settle at around $5 billion or more in annual revenues as rival drugmakers enter the space. Moderna did not immediately respond to a request for comment on booster shot sales projections, while a Pfizer spokesperson said the only forecasts the company is providing are …

Similar Posts